查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1098545

到 2028 年血液篩查世界分析的市場預測：按產品/服務、按技術（蛋白質印跡法、快速測試、下一代序列）、按應用、按地區

Blood Screening Market Forecasts to 2028 - Global Analysis By Product & Services, Technology (Western Blot Assay, Rapid Tests, Next-generation Sequencing ), Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2021年全球血液篩查市場規模將達到25.9億美元，2028年達到51.8億美元，預測期內CAGR增長10.4%。

血液篩查測試提供了醫療保健專業人員和患者做出正確醫療決策所需的重要信息，並且是成功醫療保健系統的基礎。血液篩查測試通常提供客觀和定量的測量結果，這些測量結果在醫療保健的各個階段都很有用，包括預防、檢測、診斷、治療和良好的醫療保健。

本報告調查和分析全球血液篩查市場，並提供市場規模/預測、趨勢、促進增長的因素/問題、供應商分析等。

目錄

第 1 章執行摘要

第2章前言

第三章市場趨勢分析

  • 促進因素
  • 抑制器
  • 市場機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID -19 的影響

第4章搬運工五力分析

第 5 章全球血液篩查市場：按產品/服務分類

  • 軟件和服務
  • 設備
    • 租購
    • 完成購買
  • 試劑/試劑盒
    • ELISA試劑/試劑盒
    • NAT 試劑/試劑盒

第 6 章全球血液篩查市場：按技術

  • 蛋白質印跡法
  • 快速檢測
  • 下一代測序 (NGS)
  • □聯免疫吸附試驗（ELISA）
    • 按平台

6.6 代際

    • 第三代
    • 第二代
    • 第四代及以上
    • 第一代
  • 核酸檢測（NAT）
    • 轉錄介導的擴增 (TMA)
    • 實時聚合□鍊式反應 (PCR)

第 7 章全球血液篩查市場：按應用

  • 糖尿病驗血
  • 心血管疾病的血液檢查
  • 癌症血液檢查
  • 血液疾病 血液檢查
  • 自身免疫性疾病和食物過敏測試
  • 孕期驗血
  • 肝病驗血
  • 腎損傷的血液檢查
  • 首頁-驗血監測
  • 生育力驗血

第 8 章全球血液篩查市場：按最終用戶

  • 血庫
  • 醫院

第 9 章全球血液篩查市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東/非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東

第 10 章主要發展

  • 合同、夥伴關係、合作、合資企業
  • 收購兼併
  • 推出新產品
  • 擴展
  • 其他重要策略

第 11 章公司簡介

  • Abbott Laboratories
  • Alere Inc.
  • Apex Biotechnology Corp.
  • Beckman Coulter(A Subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company
  • Biomerieux
  • Bio - Rad Laboratories, Inc.
  • F. Hoffmann - La Roche
  • Grifols
  • Hemosense Inc.
  • Luminex Corp.
  • Nova Biomedical Corp.
  • Ortho Clinical Diagnostics, Inc.
  • Roche Diagnostics
  • Siemens Healthineers(A Subsidiary of Siemens AG)
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech
Product Code: SMRC21578

According to Stratistics MRC, the Global Blood Screening Market is accounted for $2.59 billion in 2021 and is expected to reach $5.18 billion by 2028 growing at a CAGR of 10.4% during the forecast period. Blood Screening tests are the foundation of a successful healthcare system, providing critical information those healthcare providers and patients need to make the right medical decisions. Blood screening often provides objective, quantitative measurements that inform every stage of care-prevention, detection, diagnosis, treatment, and successful management of health conditions.

Market Dynamics:

Driver:

Growing number of blood donations

The increasing consciousness concerning blood safety from infectious diseases through several programs is leading to high demand for blood screening tests worldwide. Increasing cases of accidents and the prevalence of chronic diseases like cancer are creating a huge demand for blood for the treatment of the patient population. It was also validated by numerous studies that a single victim of a car accident can require up to 100 units of blood and also while receiving a chemotherapy treatment some the cancer patients require blood transfusion. Hence, a large patient pool of cancer coupled with an increase in accidental cases are generating a high demand for blood for their treatment and subsequently increasing the acceptance of blood screening tests during the forecast period.

Restraint:

High Cost

One of the major factors restraining the market growth is the lack of expenditure on healthcare infrastructure in developing countries for blood screening procedures. The high cost related to the test instruments and stringent regulatory policies is some of the factors expected to restraint the growth of the market.

Opportunity:

Introduction of Automated Molecular Platforms

Growing automation is predictable to eliminate human error during the transfusion screening process. Mostly, these screening tests influence a majority of medical decisions made in blood banks and hospitals. The introduction of such automated molecular platforms by key players has subsequently resulted in its increasing adoption in blood donation centers. This is predictable to create ample opportunity for market growth.

Threat:

Substitute technologies

Digital immunoassays are a one-step solution for single-molecule detection without requiring washing steps based on ELISA using an array of femtoliter-sized wells. This tests have seen significant interest owing to the urgent and ever-increasing demand for serological COVID-19 antibody tests that are inexpensive, rapid, simple, highly sensitive, quantitative, and minimally invasive. Therefore, a single-step, wash-free immunoassay for rapid and highly sensitive quantitative analysis of human serological IgG against SARS-CoV-2 has been developed, which requires only a single droplet of serum.

Blood banks segment is expected to be the largest during the forecast period

The blood banks segment commanded the largest share of the market. Laboratory screening of donated blood and blood products for infectious diseases is a key safety measure to protect patients and prevent the spread of serious infectious diseases. Factors such as rising blood donations and transfusion-related screenings, increasing awareness about transfusion-transmitted infections, and the rising occurrence of infectious diseases are driving the growth of this segment.

The reagents & kits segment is expected to have the highest CAGR during the forecast period

The reagents & kits segment is expected to have the highest CAGR, as reagents being a recurrent expense are widely used for immunoassays and molecular tests. Reasons such as rising blood donations and transfusion-related screenings, the increasing prevalence of infectious diseases and there has been an increase in serological testing, which has contributed to the growth of this segment.

Region with highest share:

The Asia Pacific is projected to hold the highest market share, owing to access to optimal treatment facilities and increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure. Countries in the Asia pacific provinces, such as China and India, are the hotspots for investment opportunities owing to treatment and research activities, a growing number of partnerships and healthcare modernization, growing rate of diagnosis, and quality improvisations are some of the factors motivating the market growth in the Asia Pacific region.

Region with highest CAGR:

North America is projected to have the highest CAGR, North America's largest share is primarily accredited to the growing blood transfusion-related screenings, growing prevalence of infectious diseases, rising geriatric population, need for early disease diagnosis and monitoring, increasing healthcare expenditure, and the growing adoption of advanced blood screening technologies in the province.

Key players in the market:

Some of the key players profiled in the Blood Screening Market include Abbott Laboratories, Alere Inc., Apex Biotechnology Corp, Beckman Coulter (A Subsidiary of Danaher Corporation), Becton, Dickinson and Company, Biomerieux, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche, Grifols, Hemosense Inc, Luminex Corp, Nova Biomedical Corp, Ortho Clinical Diagnostics, Inc, Roche Diagnostics, Siemens Healthineers (A Subsidiary of Siemens AG), Thermo Fisher Scientific, Inc, Trinity Biotech.

Key developments:

In October 2020: Siemens Healthineers announced shipping worldwide its laboratory-based total antibody test1 to detect the presence of SARS-CoV-2 IgM and IgG antibodies in the blood. The complete antibody test permits the identification of patients who have developed an adaptive immune response.

In February 2020: BD (US) acquired NAT Diagnostics (US), this acquisition strengthened an early-stage company developing a molecular diagnostic platform for POC testing.

In September 2021: Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche's broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.

Product & Services Covered:

  • Software and Services
  • Instruments
  • Reagents & Kits

Technology's Covered:

  • Western Blot Assay
  • Rapid Tests
  • Next-generation Sequencing (NGS)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Nucleic Acid Test (NAT)

Applications Covered:

  • Diabetes Blood Testing
  • Cardiovascular Disease Blood Testing
  • Cancer Blood Testing
  • Blood Disorder Blood Testing
  • Autoimmune Disease And Food Allergy Testing
  • Pregnancy Blood Testing
  • Liver Disorder Blood Testing
  • Kidney Disorder Blood Testing
  • Home-Monitoring Blood Testing
  • Fertility Blood Testing

End Users Covered:

  • Blood Banks
  • Hospitals

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Blood Screening Market, By Product & Service

  • 5.1 Introduction
  • 5.2 Software and Services
  • 5.3 Instruments
    • 5.3.1 Rental Purchase
    • 5.3.2 Outright Purchase
  • 5.4 Reagents & Kits
    • 5.4.1 ELISA Reagents & Kits
      • 5.4.1.1 Substrates
      • 5.4.1.2 Sample Diluents and Wash Solutions
      • 5.4.1.3 Immunosorbents
      • 5.4.1.4 Controls
      • 5.4.1.5 Conjugates
    • 5.4.2 NAT Reagents & Kits
      • 5.4.2.1 Standards and Controls
      • 5.4.2.2 Probes and Primers
      • 5.4.2.3 Labeling and Detection Reagents
      • 5.4.2.4 Enzymes and Polymerases
      • 5.4.2.5 Buffers, Nucleotides, and Solutions

6 Global Blood Screening Market, By Technology

  • 6.1 Introduction
  • 6.2 Western Blot Assay
  • 6.3 Rapid Tests
  • 6.4 Next-generation Sequencing (NGS)
  • 6.5 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.6.1 By Platform
      • 6.6.1.1 Fluorescence Immunoassay (FIA)
      • 6.6.1.2 Colorimetric Immunoassay (CI)
      • 6.6.1.3 Chemiluminescence Immunoassay (CLIA)

6.6. By Generation

    • 6.6.1 Third Generation
    • 6.6.2 Second Generation
    • 6.6.3 Fourth Generation & Above
    • 6.6.4 First Generation
  • 6.6 Nucleic Acid Test (NAT)
    • 6.6.1 Transcription-Mediated Amplification (TMA)
    • 6.6.2 Real-Time Polymerase Chain Reaction (PCR)

7 Global Blood Screening Market, By Application

  • 7.1 Introduction
  • 7.2 Diabetes Blood Testing
  • 7.3 Cardiovascular Disease Blood Testing
  • 7.4 Cancer Blood Testing
  • 7.5 Blood Disorder Blood Testing
  • 7.6 Autoimmune Disease And Food Allergy Testing
  • 7.7 Pregnancy Blood Testing
  • 7.8 Liver Disorder Blood Testing
  • 7.9 Kidney Disorder Blood Testing
  • 7.10 Home-Monitoring Blood Testing
  • 7.11 Fertility Blood Testing

8 Global Blood Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Blood Banks
  • 8.3 Hospitals

9 Global Blood Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Laboratories
  • 11.2 Alere Inc.
  • 11.3 Apex Biotechnology Corp.
  • 11.4 Beckman Coulter (A Subsidiary of Danaher Corporation)
  • 11.5 Becton, Dickinson and Company
  • 11.6 Biomerieux
  • 11.7 Bio-Rad Laboratories, Inc.
  • 11.8 F. Hoffmann-La Roche
  • 11.9 Grifols
  • 11.10 Hemosense Inc.
  • 11.11 Luminex Corp.
  • 11.12 Nova Biomedical Corp.
  • 11.13 Ortho Clinical Diagnostics, Inc.
  • 11.14 Roche Diagnostics
  • 11.15 Siemens Healthineers (A Subsidiary of Siemens AG)
  • 11.16 Thermo Fisher Scientific, Inc.
  • 11.17 Trinity Biotech

List of Tables

  • Table 1 Global Blood Screening Market Outlook, By Region (2020-2028) (US $MN)
  • Table 2 Global Blood Screening Market Outlook, By Product & Service (2020-2028) (US $MN)
  • Table 3 Global Blood Screening Market Outlook, By Software and Services (2020-2028) (US $MN)
  • Table 4 Global Blood Screening Market Outlook, By Instruments (2020-2028) (US $MN)
  • Table 5 Global Blood Screening Market Outlook, By Rental Purchase (2020-2028) (US $MN)
  • Table 6 Global Blood Screening Market Outlook, By Outright Purchase (2020-2028) (US $MN)
  • Table 7 Global Blood Screening Market Outlook, By Reagents & Kits (2020-2028) (US $MN)
  • Table 8 Global Blood Screening Market Outlook, By ELISA Reagents & Kits (2020-2028) (US $MN)
  • Table 9 Global Blood Screening Market Outlook, By NAT Reagents & Kits (2020-2028) (US $MN)
  • Table 10 Global Blood Screening Market Outlook, By Technology (2020-2028) (US $MN)
  • Table 11 Global Blood Screening Market Outlook, By Western Blot Assay (2020-2028) (US $MN)
  • Table 12 Global Blood Screening Market Outlook, By Rapid Tests (2020-2028) (US $MN)
  • Table 13 Global Blood Screening Market Outlook, By Next-generation Sequencing (NGS) (2020-2028) (US $MN)
  • Table 14 Global Blood Screening Market Outlook, By Enzyme-Linked Immunosorbent Assay (ELISA) (2020-2028) (US $MN)
  • Table 15 Global Blood Screening Market Outlook, By By Platform (2020-2028) (US $MN)
  • Table 16 Global Blood Screening Market Outlook, By By Generation (2020-2028) (US $MN)

Table17 Global Blood Screening Market Outlook, By Nucleic Acid Test (NAT) (2020-2028) (US $MN)

  • Table 18 Global Blood Screening Market Outlook, By Transcription-Mediated Amplification (TMA) (2020-2028) (US $MN)
  • Table 19 Global Blood Screening Market Outlook, By Real-Time Polymerase Chain Reaction (PCR) (2020-2028) (US $MN)
  • Table 20 Global Blood Screening Market Outlook, By Application (2020-2028) (US $MN)
  • Table 21 Global Blood Screening Market Outlook, By Diabetes Blood Testing (2020-2028) (US $MN)
  • Table 22 Global Blood Screening Market Outlook, By Cardiovascular Disease Blood Testing (2020-2028) (US $MN)
  • Table 23 Global Blood Screening Market Outlook, By Cancer Blood Testing (2020-2028) (US $MN)
  • Table 24 Global Blood Screening Market Outlook, By Blood Disorder Blood Testing (2020-2028) (US $MN)
  • Table 25 Global Blood Screening Market Outlook, By Autoimmune Disease And Food Allergy Testing (2020-2028) (US $MN)
  • Table 26 Global Blood Screening Market Outlook, By Pregnancy Blood Testing (2020-2028) (US $MN)
  • Table 27 Global Blood Screening Market Outlook, By Liver Disorder Blood Testing (2020-2028) (US $MN)
  • Table 28 Global Blood Screening Market Outlook, By Kidney Disorder Blood Testing (2020-2028) (US $MN)
  • Table 29 Global Blood Screening Market Outlook, By Home-Monitoring Blood Testing (2020-2028) (US $MN)
  • Table 30 Global Blood Screening Market Outlook, By Fertility Blood Testing (2020-2028) (US $MN)
  • Table 31 Global Blood Screening Market Outlook, By End User (2020-2028) (US $MN)
  • Table 32 Global Blood Screening Market Outlook, By Blood Banks (2020-2028) (US $MN)
  • Table 33 Global Blood Screening Market Outlook, By Hospitals (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.